Praluent Global Regulatory Status

FDA Approval History and Original Indication

The FDA approved alirocumab (Praluent) on July 24, 2015, under BLA 125559, making it the first PCSK9 inhibitor to reach the U.S. market [1]. The original indication covered adults with HeFH or clinical ASCVD who required additional LDL-C lowering as an adjunct to diet and maximally tolerated statin therapy.

Approval rested on a pool of ten Phase 3 ODYSSEY trials enrolling more than 5,000 patients. In ODYSSEY COMBO II (N=720), alirocumab 75 mg every two weeks reduced LDL-C by 50.6% from baseline at week 24, compared with 20.7% for ezetimibe [2]. The FDA granted priority review based on the unmet need in patients whose LDL-C remained above goal despite high-intensity statins. Regeneron and Sanofi co-developed the drug, with Regeneron leading U.S. commercialization and Sanofi handling markets outside the United States.

The initial prescribing information specified two dose levels: 75 mg and 150 mg administered subcutaneously every two weeks. A dose-adjustment strategy allowed clinicians to start at 75 mg and titrate to 150 mg if LDL-C response was insufficient after 4 to 8 weeks [1].

EMA Marketing Authorization

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended authorization on July 23, 2015, and the European Commission granted marketing authorization on September 23, 2015 [3]. The approved indication in Europe mirrored the FDA label: primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia, as an adjunct to diet, in combination with a statin or other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated.

The EMA's European Public Assessment Report (EPAR) highlighted that alirocumab consistently achieved LDL-C reductions between 44% and 61% across the ODYSSEY program, depending on the comparator and patient population [3]. Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved alirocumab in June 2016, followed by Health Canada approval in the same year.

ODYSSEY OUTCOMES and the Cardiovascular Label Expansion

The ODYSSEY OUTCOMES trial (N=18,924) was the regulatory gateway to a cardiovascular risk-reduction claim [4]. This double-blind, placebo-controlled trial enrolled patients who had experienced an acute coronary syndrome (ACS) event 1 to 12 months before randomization and were on high-intensity or maximum-tolerated statin therapy. The primary endpoint was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization.

At a median follow-up of 2.8 years, alirocumab reduced the primary MACE endpoint by 15% relative to placebo (HR 0.85; 95% CI 0.78-0.93; P=0.0003) [4]. Absolute LDL-C reduction from a baseline of approximately 92 mg/dL reached a mean of 54.7 mg/dL at month 4 in the alirocumab group. A pre-specified analysis showed that patients with baseline LDL-C of 100 mg/dL or higher experienced a 24% relative reduction in MACE (HR 0.76; 95% CI 0.65-0.87) [4].

An exploratory all-cause mortality analysis showed a nominally significant 15% reduction with alirocumab (HR 0.85; 95% CI 0.73-0.98), though this was not adjusted for multiplicity in the hierarchical testing procedure [4]. Dr. Philippe Gabriel Steg, co-principal investigator of ODYSSEY OUTCOMES, stated: "The cardiovascular benefit of alirocumab was consistent across subgroups and appeared most pronounced in patients entering the trial with LDL cholesterol at or above 100 mg/dL" [4].

Based on these data, the FDA approved a supplemental BLA in April 2019 adding the following indication: to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease [5]. The EMA's CHMP adopted a positive opinion for the same CV indication in 2019, and the European Commission updated the marketing authorization accordingly [3].

Current Prescribing Label: Dosing, Indications, and Warnings

The current FDA-approved prescribing information for Praluent lists two indications [5]. The first covers LDL-C reduction in adults with HeFH or clinical ASCVD as an adjunct to diet and maximally tolerated statin therapy. The second covers cardiovascular risk reduction in adults with established CVD.

Three dosing regimens are available. Patients may receive 75 mg every 2 weeks (Q2W), 150 mg Q2W, or 300 mg every 4 weeks (Q4W). The 300 mg Q4W option was added in a label supplement to improve convenience and adherence for patients who prefer monthly injections [5]. The label recommends measuring LDL-C 4 to 8 weeks after initiation or titration to assess response.

Labeled warnings include hypersensitivity reactions (reported in 0.6% of alirocumab-treated patients vs. 0.2% on placebo across clinical trials) and injection-site reactions, which occurred in 7.0% of alirocumab patients versus 5.1% on placebo [5]. The label does not carry a boxed warning. No Risk Evaluation and Mitigation Strategy (REMS) is required.

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol positions PCSK9 inhibitors, including alirocumab, as add-on therapy for patients at very high cardiovascular risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [6]. The guideline states: "In patients at very high risk whose LDL-C level remains ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable" [6].

Post-Market Safety Surveillance

Post-market safety data have largely confirmed the clinical trial safety profile. The FDA Adverse Event Reporting System (FAERS) has not identified new safety signals beyond those characterized during Phase 3 development [7]. Injection-site reactions and upper respiratory tract infections remain the most commonly reported adverse events in real-world pharmacovigilance.

Neurocognitive effects received specific scrutiny during and after the ODYSSEY program. The ODYSSEY OUTCOMES trial included a prospective neurocognitive substudy that found no significant difference in neurocognitive adverse events between alirocumab and placebo, even among patients who achieved very low LDL-C levels below 25 mg/dL [4]. The FDA label includes a statement noting that neurocognitive events were reported but were not increased relative to placebo.

Immunogenicity data from the integrated ODYSSEY program showed that binding anti-drug antibodies developed in approximately 5.1% of alirocumab-treated patients, but neutralizing antibodies were rare (less than 1%) and had no apparent effect on efficacy or safety [5]. Long-term open-label extension studies through 4 years of treatment have demonstrated sustained LDL-C lowering with no new safety concerns [8].

The EMA's Periodic Safety Update Reports (PSURs) have reached the same conclusion: the benefit-risk profile of alirocumab remains favorable for the approved indications [3]. No post-marketing restrictions, label contraindications, or additional risk minimization measures have been mandated by either the FDA or EMA since approval.

Regulatory Comparison with Evolocumab

Evolocumab (Repatha), the other approved PCSK9 inhibitor, received FDA approval on August 27, 2015, approximately one month after alirocumab [9]. Both drugs share the same mechanism (anti-PCSK9 monoclonal antibody) and similar approved indications, though there are regulatory and labeling differences worth noting.

Evolocumab's cardiovascular indication, based on the FOURIER trial (N=27,564), was approved in December 2017, roughly 16 months before alirocumab's CV expansion [9]. FOURIER demonstrated a 15% relative risk reduction in the primary composite endpoint of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization (HR 0.85; 95% CI 0.79-0.92; P<0.001) [10]. The primary endpoint definitions differed between FOURIER and ODYSSEY OUTCOMES: FOURIER included coronary revascularization while ODYSSEY OUTCOMES did not.

Evolocumab carries an additional FDA-approved indication for homozygous familial hypercholesterolemia (HoFH) in patients aged 10 years and older, an indication that alirocumab does not hold [9]. Alirocumab's ODYSSEY OUTCOMES trial showed a nominally significant all-cause mortality signal (HR 0.85; P=0.026), while FOURIER did not demonstrate a mortality benefit (HR 1.04; 95% CI 0.91-1.19) [4][10]. Neither result was part of a pre-specified confirmatory analysis with multiplicity correction.

Access, Coverage, and Formulary Status

Payer coverage for PCSK9 inhibitors has been a persistent barrier since approval. Initial list prices for both alirocumab and evolocumab were approximately $14,000 per year. In 2018, Regeneron and Sanofi reduced the list price of Praluent by 60% to approximately $5,850 per year, contingent on outcomes-based contracts with payers [11].

The Institute for Clinical and Economic Review (ICER) initially judged PCSK9 inhibitors to be cost-ineffective at launch pricing but revised its assessment following the price reduction and the ODYSSEY OUTCOMES cardiovascular data, estimating that alirocumab could meet commonly cited cost-effectiveness thresholds of $100,000-$150,000 per quality-adjusted life year in the post-ACS population [12].

Prior authorization requirements remain standard across most commercial and Medicare Part D plans. Typical criteria require documentation of ASCVD or HeFH, LDL-C above a plan-specific threshold (often 70 mg/dL for ASCVD, 100 mg/dL for HeFH), maximally tolerated statin therapy, and trial of ezetimibe [13]. Some plans have eased PA requirements following CMS guidance encouraging broader access to PCSK9 inhibitors for high-risk Medicare beneficiaries.

Biosimilar and Patent Considerations

Alirocumab is a biologic approved under the Public Health Service Act (Section 351(a)), making it subject to the Biologics Price Competition and Innovation Act (BPCIA) rather than Hatch-Waxman generic drug provisions. The 12-year biologics exclusivity period runs from the original July 2015 approval, placing the earliest possible biosimilar approval date around July 2027 [14].

Patent litigation between Regeneron/Sanofi and Amgen over PCSK9 antibody patent claims resulted in a complex legal history. In 2019, the U.S. Court of Appeals for the Federal Circuit vacated Amgen's broad PCSK9 antibody genus patents on enablement grounds, a decision upheld by the Supreme Court in Amgen v. Sanofi (2023), which reinforced the requirement that patents must enable the full scope of their claims [15]. This ruling cleared a significant intellectual property obstacle for future biosimilar applicants.

No biosimilar application for alirocumab has been publicly disclosed as of May 2026. The timeline for biosimilar PCSK9 inhibitors will depend on manufacturer interest, the complexity of monoclonal antibody biosimilar development, and the evolving market size for the class.